摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 6-benzyloxycarbonylamino-5-O-[5-tert-butoxycarbonylamino-5-deoxy-2,3-O-(3-pentylidene)-β-D-ribo-pentofuranosyl]-6-deoxy-2,3-O-isopropylidene-1-(uracil-1-yl)-β-D-glycelo-L-talo-heptofuranuronate | 1211774-34-3

中文名称
——
中文别名
——
英文名称
tert-butyl 6-benzyloxycarbonylamino-5-O-[5-tert-butoxycarbonylamino-5-deoxy-2,3-O-(3-pentylidene)-β-D-ribo-pentofuranosyl]-6-deoxy-2,3-O-isopropylidene-1-(uracil-1-yl)-β-D-glycelo-L-talo-heptofuranuronate
英文别名
tert-butyl (2S,3S)-3-[[(3aR,4S,6R,6aR)-2,2-diethyl-6-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]oxy]-3-[(3aR,4R,6R,6aR)-4-(2,4-dioxopyrimidin-1-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]-2-(phenylmethoxycarbonylamino)propanoate
tert-butyl 6-benzyloxycarbonylamino-5-O-[5-tert-butoxycarbonylamino-5-deoxy-2,3-O-(3-pentylidene)-β-D-ribo-pentofuranosyl]-6-deoxy-2,3-O-isopropylidene-1-(uracil-1-yl)-β-D-glycelo-L-talo-heptofuranuronate化学式
CAS
1211774-34-3
化学式
C41H58N4O15
mdl
——
分子量
846.929
InChiKey
WSNKBMPKBGWZDO-NRGHJKMASA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    60
  • 可旋转键数:
    18
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.68
  • 拓扑面积:
    217
  • 氢给体数:
    3
  • 氢受体数:
    15

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    tert-butyl 6-benzyloxycarbonylamino-5-O-[5-tert-butoxycarbonylamino-5-deoxy-2,3-O-(3-pentylidene)-β-D-ribo-pentofuranosyl]-6-deoxy-2,3-O-isopropylidene-1-(uracil-1-yl)-β-D-glycelo-L-talo-heptofuranuronate 在 palladium 10% on activated carbon 、 氢气 作用下, 以 甲醇 为溶剂, 反应 0.5h, 生成 tert-butyl (2S,3S)-3-[[(3aR,4S,6R,6aR)-2,2-diethyl-6-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]oxy]-3-[(3aR,4R,6R,6aR)-4-(2,4-dioxopyrimidin-1-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]-2-aminopropanoate
    参考文献:
    名称:
    (-)-莫拉霉素D2及其差向异构体的全合成
    摘要:
    描述了(-)-muraymycin(MRY)D2及其差向异构体(抗菌核苷天然产物)的第一个全合成的完整细节。该方法的关键战略要素包括尿素二肽部分的制备在含有所述muraymycins发现升-外延-capreomycidine经由所述氨基磺酸酯的氮宾C-H插入10通过的Ugi 4和所述完全受保护muraymycin骨架在后期阶段-组分反应。因此,将氨基磺酸盐10与10 mol%的Rh 2(esp)2催化剂的丁腈CH插入,以47%的收率得到环状氨基磺酸盐11a和11b(11a:11b= 1:2.0)。环状胍骨架的构建是通过HgBr 2促进的42的环化作用,然后在草ath嗪烷环的乙酰化作用下进行脱磺酰作用而得到的,从而以良好的收率得到43。通过选择性去除Cbz基团的醇的的得到的胺44用MESC(= O)反应-升-Val-O-吨-Bu(38),以提供45,将其氧化为羧酸46。反应46,异腈51,异戊醛和2
    DOI:
    10.1021/jo9027193
  • 作为产物:
    描述:
    6-benzyloxycarbonylamino-5-O-[5-tert-butoxycarbonylamino-5-deoxy-2,3-O-(3-pentylidene)-β-D-ribo-pentofuranosyl]-6-deoxy-2,3-O-isopropylidene-1-(uracil-1-yl)-β-D-glycero-L-talo-heptofuranuronate叔丁基三氯乙酰亚胺酯三氟化硼乙醚 作用下, 以 二氯甲烷 为溶剂, 反应 18.0h, 以66%的产率得到tert-butyl 6-benzyloxycarbonylamino-5-O-[5-tert-butoxycarbonylamino-5-deoxy-2,3-O-(3-pentylidene)-β-D-ribo-pentofuranosyl]-6-deoxy-2,3-O-isopropylidene-1-(uracil-1-yl)-β-D-glycelo-L-talo-heptofuranuronate
    参考文献:
    名称:
    (-)-莫拉霉素D2及其差向异构体的全合成
    摘要:
    描述了(-)-muraymycin(MRY)D2及其差向异构体(抗菌核苷天然产物)的第一个全合成的完整细节。该方法的关键战略要素包括尿素二肽部分的制备在含有所述muraymycins发现升-外延-capreomycidine经由所述氨基磺酸酯的氮宾C-H插入10通过的Ugi 4和所述完全受保护muraymycin骨架在后期阶段-组分反应。因此,将氨基磺酸盐10与10 mol%的Rh 2(esp)2催化剂的丁腈CH插入,以47%的收率得到环状氨基磺酸盐11a和11b(11a:11b= 1:2.0)。环状胍骨架的构建是通过HgBr 2促进的42的环化作用,然后在草ath嗪烷环的乙酰化作用下进行脱磺酰作用而得到的,从而以良好的收率得到43。通过选择性去除Cbz基团的醇的的得到的胺44用MESC(= O)反应-升-Val-O-吨-Bu(38),以提供45,将其氧化为羧酸46。反应46,异腈51,异戊醛和2
    DOI:
    10.1021/jo9027193
点击查看最新优质反应信息

文献信息

  • Total Synthesis of (−)-Muraymycin D2 and Its Epimer
    作者:Tetsuya Tanino、Satoshi Ichikawa、Motoo Shiro、Akira Matsuda
    DOI:10.1021/jo9027193
    日期:2010.3.5
    desulfonylation upon acetolysis of the oxathiazinane ring to give 43 in good yield. The amine obtained by selective removal of the Cbz group of the alcohol 44 was reacted with MeSC(═O)-l-Val-O-t-Bu (38) to provide 45, which was oxidized to the carboxylic acid 46. Reaction of 46, isonitrile 51, isovaleraldehyde, and 2,4-dimethoxybenzylamine furnished the desired Ugi products, the final deprotection of which successfully
    描述了(-)-muraymycin(MRY)D2及其差向异构体(抗菌核苷天然产物)的第一个全合成的完整细节。该方法的关键战略要素包括尿素二肽部分的制备在含有所述muraymycins发现升-外延-capreomycidine经由所述氨基磺酸酯的氮宾C-H插入10通过的Ugi 4和所述完全受保护muraymycin骨架在后期阶段-组分反应。因此,将氨基磺酸盐10与10 mol%的Rh 2(esp)2催化剂的丁腈CH插入,以47%的收率得到环状氨基磺酸盐11a和11b(11a:11b= 1:2.0)。环状胍骨架的构建是通过HgBr 2促进的42的环化作用,然后在草ath嗪烷环的乙酰化作用下进行脱磺酰作用而得到的,从而以良好的收率得到43。通过选择性去除Cbz基团的醇的的得到的胺44用MESC(= O)反应-升-Val-O-吨-Bu(38),以提供45,将其氧化为羧酸46。反应46,异腈51,异戊醛和2
  • Synthesis and Biological Evaluation of Muraymycin Analogues Active against Anti-Drug-Resistant Bacteria
    作者:Tetsuya Tanino、Satoshi Ichikawa、Bayan Al-Dabbagh、Ahmed Bouhss、Hiroshi Oyama、Akira Matsuda
    DOI:10.1021/ml100057z
    日期:2010.9.9
    Muraymycin analogues with a lipophilic substituent were synthesized using an Ugi four-component assemblage. This approach provides ready access to a range of analogues simply by altering the aldehyde component. The impact of the lipophilic substituent on the antibacterial activity was very large, and analogues 7b-e and 8b-e exhibited good activity against a range of Gram;positive bacterial pathogens including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. This study also showed that the accessory urea-dipeptide motif contributes to MraY inhibitory and antibacterial activity. The knowledge obtained from our structure activity relationship study of muraymycins provides further direction toward the design of potent MraY inhibitors. This study has set the stage for the generation of novel antibacterial "lead" compounds based on muraymycins.
  • Mechanistic Analysis of Muraymycin Analogues: A Guide to the Design of MraY Inhibitors
    作者:Tetsuya Tanino、Bayan Al-Dabbagh、Dominique Mengin-Lecreulx、Ahmed Bouhss、Hiroshi Oyama、Satoshi Ichikawa、Akira Matsuda
    DOI:10.1021/jm200906r
    日期:2011.12.22
    The systematic structure activity relationship (SAX) of the muraymycins (MRYs) using an Ugi four-component reaction (U4CR) was investigated. The impact of the lipophilic substituent on antibacterial activity was significant, and the analogues 8 and 9 having a lipophilic side chain exhibited good activity against a range of Gram-positive bacterial pathogens, including MRSA and VRE. Further investigation of compounds 8 and 9 revealed these analogues to be selective inhibitors of the MraY transferase and nontoxic to HepG2 cells. The SAX of the accessory urea peptide moiety indicated that it could be simplified. Our SAX study of the MRYs suggests a probable mechanism for inhibition of the MraY, where the inner moiety of the urea dipeptide motif interacts with the carbohydrate recognition domain in the cytoplasmic loop S. The predicted binding model would provide further direction toward the design of potent MraY inhibitors. This study has set the stage for the generation of novel antibacterial "lead" compounds based on MRYs.
  • Function-Oriented Synthesis of Simplified Caprazamycins: Discovery of Oxazolidine-Containing Uridine Derivatives as Antibacterial Agents against Drug-Resistant Bacteria
    作者:Kensuke Ii、Satoshi Ichikawa、Bayan Al-Dabbagh、Ahmed Bouhss、Akira Matsuda
    DOI:10.1021/jm100243n
    日期:2010.5.13
    The rational simplification of the caprazamycin (CPZ) class of nucleoside natural products was carried out to address their molecular complexity. First, analogues 6-8, where the diazepanone ring of the CPZ was removed and a lipophilic side chain was attached to either the C-7' or N(6') atom, were used to investigate the conformation activity relationship. On the basis of this relationship, we designed the oxazolidine-containing uridine derivatives 18-21 by restricting the conformation of 6-8. As a result, the 'Bu ester derivatives 20 were found to be the most active against a range of bacterial strains containing VRE with a potency similar to that of the parent CPZs. This study provides a novel strategy for the development of a new type of antibacterial agent effective against drug-resistant bacteria.
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物